The Central Drugs Standard Control Organisation (CDSCO) has directed state drug authorities to ensure that all pharmaceutical manufacturing units comply with international quality standards by January 2026. The regulator has made it clear that it will not grant any further deadline extensions, despite multiple industry appeals. The directive follows renewed reports linking contaminated cough syrup to the deaths of 24 children in central India since September.
Revised Schedule M to Be Enforced with Immediate Inspections
CDSCO has instructed state regulators to begin inspections to verify compliance with the revised Schedule M of the Drugs and Cosmetics Rules. These updated norms, aligned with World Health Organization (WHO) standards, mandate stronger controls to prevent cross-contamination, improve traceability, and enhance batch testing protocols. “If any manufacturing unit is found non-compliant during inspections, strict action shall be initiated,” the directive signed by Drugs Controller General Rajeev Singh Raghuvanshi stated. States have been told to treat the enforcement process as a “top priority.”
Global Safety Concerns Prompt Regulatory Push
India tightened its pharmaceutical quality regulations in late 2023 after authorities linked Indian-made cough syrups to the deaths of more than 140 children in Gambia, Uzbekistan, and Cameroon. These incidents triggered international scrutiny and damaged India’s reputation as the “pharmacy of the world.” Large pharmaceutical companies have already implemented the revised standards, meeting the June 2024 deadline. However, regulators allowed small and medium manufacturers additional time until December 2025. Regulators have now withdrawn any possibility of further extensions.
Industry Warns of Impact on Smaller Firms
Industry associations have expressed concern over the financial burden of upgrading facilities, cautioning that stricter compliance could force many small- and medium-sized enterprises (SMEs) to shut down. “What good is quality if there is no affordability?” said Jagdeep Singh, Secretary of the SME Pharma Industries Confederation. He warned that the new requirements could lead to widespread factory closures, job losses, and increased drug prices for consumers.
Renewed Urgency After Latest Contamination Reports
Regulatory tightening has gained renewed urgency after investigators linked the recent deaths of children in Madhya Pradesh to toxic cough syrup batches. The incident has intensified pressure on authorities to enforce compliance and restore trust in India’s pharmaceutical manufacturing standards. As reported by businessworld.in, with inspections now underway and no further extensions offered, the next year will be pivotal for the industry’s operational and regulatory realignment.
